Status:
Recruiting
Disease Site:
Genitourinary
Diagnosis:
- Rare GU tumors
Phase:
Official Title:
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
NCT ID:
NCT#03866382
Link to Full Details:
Investigators:
- Dr. Mark Olsen
Description:
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Eligibility:
Male and Female – 18 years and older
Inclusion Criteria:
- Metastatic disease
- Measurable disease including bone disease
- Tissue available for central path review
Exclusion Criteria:
- Chemotherapy within past 2 weeks
- No concomitant warfarin
- No evidence of tumor invading GI tract